Medical, Drugs, Pharmaceuticals And Diseases Information

Tacrine is a parasympathomimetic and a centrally acting cholinesterase inhibitor. It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer’s disease, and was marketed under the brand name Cognex. The use of tacrine is limited by poor oral bioavailability, the necessity for four-times daily dosing, and considerable adverse drug reactions (including nausea, diarrhea, urinary incontinence and hepatotoxicity) such that few patients could tolerate therapeutic doses. Other newer cholinesterase inhibitors, such as donepezil, are now preferred over tacrine.

Dimebolin Hydrochloride - brand name Dimebon is an antihistamine drug. Recently dimebolin has attracted interest after being shown to have positive effects on persons suffering from Alzheimer’s disease. Preliminary results from human trials have also been promising. In an initial six-month phase trial, results have shown that at 12 months there was significant improvement over placebo. Dimebolin showed promising results in a Phase III-equivalent double blind trial in Russia with mild-moderate stage patients. Dimebolin is an orally active small molecule that has been shown to inhibit brain cell death in preclinical studies of Alzheimer’s disease and Huntington’s disease, making it a potential treatment for these and other neurodegenerative diseases. Research suggests that it may also have cognition-enhancing effects in healthy individuals.